Logo

NeoGenesis Signs Discovery Collaboration with Amgen

Aug 04, 2003

NEW YORK, Aug. 4 (GenomeWeb News) - Chemical genomics firm NeoGenesis Pharmaceuticals said today that it has signed a multi-year drug discovery collaboration agreement with Amgen.

 

NeoGenesis will use its ALIS (Automated Ligand Identification System) platform along with its compound libraries and lead optimization technologies in the project, which will focus on the discovery of small-molecule drugs for cancer, neurodegenerative diseases, and inflammatory diseases.

 

The company will receive research funding, milestone payments, and royalties based on the successful development of drug candidates.

 

NeoGenesis, headquartered in Cambridge, Mass., has similar partnerships with Aventis Pharma, Biogen, Celltech, Japan Tobacco, Merck, Mitsubishi Pharma, Pfizer, Schering-Plough, and Tularik.

Breaking News
The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.